Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12»
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Journal:  Consensus Recommendations for Treatment of the Upper Face With LetibotulinumtoxinA. (Pubmed Central) -  Sep 30, 2024   
    The panelists provided recommendations for treating forehead horizontal lines, glabellar frown lines, and lateral canthal lines. The guidelines developed by the panel will support clinical practitioners of all skill levels in providing safe and effective aesthetic treatments of the forehead, glabellar complex, and lateral canthal lines with letibotulinumtoxinA.
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma, Jeuveau (prabotulinumtoxinA-xvfs) / AEON Biopharma
    Preclinical, Journal:  Investigating the impact of botulinum toxin type a on the migration of normal human dermal fibroblasts: An in (Pubmed Central) -  Sep 26, 2024   
    The guidelines developed by the panel will support clinical practitioners of all skill levels in providing safe and effective aesthetic treatments of the forehead, glabellar complex, and lateral canthal lines with letibotulinumtoxinA. Different types and dilutions of BoNT-A demonstrated variable inhibitory effects on NHDF migration in
  • ||||||||||  Botulax (botulinum toxin type A) / Hugel, Croma Pharma
    P2 data, Journal:  A Multi-center Phase II Study Evaluating the Safety and Efficacy of Botulax (Pubmed Central) -  Apr 24, 2024   
    Different types and dilutions of BoNT-A demonstrated variable inhibitory effects on NHDF migration in BTA administration of at least 48 U for BMH is more cost-effective than high-dose units and has a low risk of side effects.
  • ||||||||||  Botulax (botulinum toxin type A) / Hugel, Croma Pharma
    Journal:  Use of LetibotulinumtoxinA for Aesthetic Treatment of Asians: A Consensus. (Pubmed Central) -  Oct 22, 2023   
    Panelists proposed individualized treatment plans for botulinum toxin type A (BTxA) in three aspects of wrinkle removal, contour adjustment, and face lifting in Asians based on their extensive experience and facial anatomy. When using different BTxA, clinicians should start with a conservative dose and carefully individualize the treatment for each patien and adjust it according to the feedback to obtain a higher satisfaction level.
  • ||||||||||  Botulax (botulinum toxin type A) / Hugel, Croma Pharma
    Journal:  Commentary on: Use of LetibotulinumtoxinA for Aesthetic Treatment of Asians: A Consensus. (Pubmed Central) -  Sep 1, 2023   
    When using different BTxA, clinicians should start with a conservative dose and carefully individualize the treatment for each patien and adjust it according to the feedback to obtain a higher satisfaction level. No abstract available
  • ||||||||||  Botulax (botulinum toxin type A) / Hugel, Croma Pharma, Evosyal (prabotulinumtoxin A) / Daewoong Pharma, AEON Biopharma
    Differences in antibody responses of intradermal and intramuscular injections of botulinum toxin type A (Level 3 - Nicoll 2) -  Apr 24, 2023 - Abstract #WCD2023WCD_1483;    
    MATERIALS AND One hundred subjects were divided into intradermal and intramuscular groups, and each group was equally divided into 5 subgroups for using 5 types of BoNT/A (incobotulinumtoxinA, onabotulinumtoxinA, abobotulinumtoxinA, letibotulinumtoxinA, and prabotulinumtoxinA). Intramuscular BoNT/A injections could be preferable for facial treatment to reduce the antibody against BoNT/A formation
  • ||||||||||  Review, Journal:  Cosmetic Treatment Using Botulinum Toxin in the Oral and Maxillofacial Area: A Narrative Review of Esthetic Techniques. (Pubmed Central) -  Feb 28, 2023   
    There are several FDA-approved BoNTs (obabotuli-numtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, letibotulinumtoxinA, prabotulinumtox-inA, daxibotulinumtoxinA, rimbotulinumtoxinB) and novel BoNTs on the market...This paper can serve as a practical illustrative guide and reference for optimal, safe injection areas and effective doses for application of BoNT in the face and oral and maxillofacial area. The history of BoNT indications, contraindications, and complications, and the merits of ultrasonography (US)-assisted injections are also discussed.
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    New P3 trial:  Efficacy and Safety Assessment of Botulax (clinicaltrials.gov) -  May 17, 2022   
    P3,  N=500, Completed, 
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Clinical Trial to Compare the Safety and Efficacy of Botulax (clinicaltrials.gov) -  Apr 22, 2022   
    P1,  N=38, Completed, 
    Differences between certain BoNT unit scales were also confirmed. Not yet recruiting --> Completed | Trial completion date: Jul 2020 --> Oct 2021 | Trial primary completion date: Jul 2020 --> Apr 2021
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Trial completion:  Evaluate the Safety and Efficacy of Botulax (clinicaltrials.gov) -  Apr 15, 2022   
    P3,  N=240, Completed, 
    Not yet recruiting --> Completed | Trial completion date: Jul 2020 --> Oct 2021 | Trial primary completion date: Jul 2020 --> Apr 2021 Recruiting --> Completed
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Evaluate the Safety and Efficacy of Botulax (clinicaltrials.gov) -  Apr 15, 2022   
    P1,  N=38, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial completion date: Jun 2020 --> Oct 2021 | Trial primary completion date: Jun 2020 --> Apr 2021
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Trial completion, Trial completion date:  Evaluate the Safety and Efficacy of Botulax (clinicaltrials.gov) -  Nov 16, 2021   
    P2,  N=80, Completed, 
    The SPR study seemed to be useful for evaluating the potency by specifically measuring intact 19S neurotoxin, and these results provide new insights for assessing different BoNT products. Recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2021
  • ||||||||||  Botulax (botulinum toxin type A) / Hugel, Croma Pharma
    Clinical, Journal:  Botulinum Toxin Type-A (Botulax) Treatment in Patients with Intractable Chronic Occipital Neuralgia: A Pilot Study. (Pubmed Central) -  Jul 2, 2021   
    There were no adverse events or changes from baseline in serologic studies and vital signs in any of the participants. The treatment's pain-relieving effects were confirmed through regular, 12-week follow-ups, confirming the safety and effectiveness of BTX-A on chronic ON and suggesting that this method is an effective, novel alternative option for chronic ON treatment.
  • ||||||||||  Botulax (botulinum toxin type A) / Hugel, Croma Pharma, daxibotulinumtoxinA (RT002) / Revance Therap
    Journal:  Updates on Botulinum Neurotoxins in Dermatology. (Pubmed Central) -  Jan 6, 2021   
    Being the most popular non-surgical cosmetic procedure, botulinum neurotoxin (BoNT) injections are increasingly of interest to all cosmetic practitioners across the globe. This article serves to update readers on the new botulinum toxins that are currently in development or close to market in the USA and Canada, including daxibotulinumtoxin A, prabotulinumtoxin A, letibotulinumtoxin A, and botulinum toxin E. Despite having relatively similar characteristics and equivalent clinical efficacies, these neurotoxins manifest a multitude of unique potential advantages that will be explored in this review, including but not limited to a longer duration of action, the absence of animal-derived components or human albumin, and a rapid onset with short duration of action.
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    New P2 trial:  Evaluate the Safety and Efficacy of Botulax (clinicaltrials.gov) -  Jun 22, 2020   
    P2,  N=80, Recruiting, 
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Trial initiation date:  Clinical Trial to Compare the Safety and Efficacy of Botulax (clinicaltrials.gov) -  Jan 15, 2020   
    P1,  N=38, Not yet recruiting, 
    This article serves to update readers on the new botulinum toxins that are currently in development or close to market in the USA and Canada, including daxibotulinumtoxin A, prabotulinumtoxin A, letibotulinumtoxin A, and botulinum toxin E. Despite having relatively similar characteristics and equivalent clinical efficacies, these neurotoxins manifest a multitude of unique potential advantages that will be explored in this review, including but not limited to a longer duration of action, the absence of animal-derived components or human albumin, and a rapid onset with short duration of action. Initiation date: Nov 2019 --> Mar 2020
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    New P1 trial:  Evaluate the Safety and Efficacy of Botulax (clinicaltrials.gov) -  Dec 3, 2019   
    P1,  N=38, Recruiting, 
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Trial completion, Trial completion date, Trial primary completion date:  BLESS I: Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I (clinicaltrials.gov) -  Feb 26, 2019   
    P3,  N=700, Completed, 
    Initiation date: Nov 2019 --> Mar 2020 Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Dec 2018
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Trial completion, Trial completion date, Trial primary completion date:  BLESS II: Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II (clinicaltrials.gov) -  Feb 26, 2019   
    P3,  N=200, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Dec 2018
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Trial completion date, Trial primary completion date:  BLESS II: Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II (clinicaltrials.gov) -  Aug 2, 2018   
    P3,  N=200, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Dec 2018 Trial completion date: Jun 2018 --> Sep 2018 | Trial primary completion date: Jun 2018 --> Sep 2018
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Enrollment open:  Evaluate the Safety and Efficacy of Botulax (clinicaltrials.gov) -  Jan 26, 2018   
    P3,  N=240, Recruiting, 
    Trial completion date: Jun 2018 --> Sep 2018 | Trial primary completion date: Jun 2018 --> Sep 2018 Active, not recruiting --> Recruiting
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    New P3 trial:  Evaluate the Safety and Efficacy of Botulax (clinicaltrials.gov) -  Jan 23, 2018   
    P3,  N=240, Active, not recruiting, 
  • ||||||||||  Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
    Trial completion, Trial primary completion date:  Phase III Study of Botulax (clinicaltrials.gov) -  May 4, 2015   
    P3,  N=186, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Nov 2013 --> May 2014